LOCUS       NP_996839                509 aa            linear   PRI 21-SEP-2008
DEFINITION  preferentially expressed antigen in melanoma [Homo sapiens].
ACCESSION   NP_996839
VERSION     NP_996839.1  GI:46249373
DBSOURCE    REFSEQ: accession NM_206956.1
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
            Catarrhini; Hominidae; Homo.
REFERENCE   1  (residues 1 to 509)
  AUTHORS   Partheen,K., Levan,K., Osterberg,L., Claesson,I., Fallenius,G.,
            Sundfeldt,K. and Horvath,G.
  TITLE     Four potential biomarkers as prognostic factors in stage III serous
            ovarian adenocarcinomas
  JOURNAL   Int. J. Cancer 123 (9), 2130-2137 (2008)
   PUBMED   18709641
  REMARK    GeneRIF: the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as
            prognostic factors for patients with stage III serous ovarian
            adenocarcinomas.
REFERENCE   2  (residues 1 to 509)
  AUTHORS   Arons,E., Suntum,T., Margulies,I., Yuan,C., Stetler-Stevenson,M.
            and Kreitman,R.J.
  TITLE     PRAME expression in hairy cell leukemia
  JOURNAL   Leuk. Res. 32 (9), 1400-1406 (2008)
   PUBMED   18295331
  REMARK    GeneRIF: We conclude that HCL and CLL differ in PRAME
            overexpression, and that basal normal expression of PRAME may limit
            its usefulness for following patients with minimal residual CLL or
            HCL.
REFERENCE   3  (residues 1 to 509)
  AUTHORS   Epping,M.T., Hart,A.A., Glas,A.M., Krijgsman,O. and Bernards,R.
  TITLE     PRAME expression and clinical outcome of breast cancer
  JOURNAL   Br. J. Cancer 99 (3), 398-403 (2008)
   PUBMED   18648365
  REMARK    GeneRIF: Multivariable analysis indicated that PRAME is an
            independent marker of shortened metastasis-free interval in
            patients who did not receive adjuvant chemotherapy. PRAME
            expression was associated with tumour grade and negative oestrogen
            receptor status
REFERENCE   4  (residues 1 to 509)
  AUTHORS   Doolan,P., Clynes,M., Kennedy,S., Mehta,J.P., Crown,J. and
            O'Driscoll,L.
  TITLE     Prevalence and prognostic and predictive relevance of PRAME in
            breast cancer
  JOURNAL   Breast Cancer Res. Treat. 109 (2), 359-365 (2008)
   PUBMED   17624586
  REMARK    GeneRIF: PRAME mRNA expression may be a useful prognostic and
            predictive marker for breast cancer.
REFERENCE   5  (residues 1 to 509)
  AUTHORS   Steinbach,D., Pfaffendorf,N., Wittig,S. and Gruhn,B.
  TITLE     PRAME expression is not associated with down-regulation of retinoic
            acid signaling in primary acute myeloid leukemia
  JOURNAL   Cancer Genet. Cytogenet. 177 (1), 51-54 (2007)
   PUBMED   17693191
  REMARK    GeneRIF: PRAME expression is not associated with down-regulation of
            retinoic acid signaling in primary acute myeloid leukemia.
REFERENCE   6  (residues 1 to 509)
  AUTHORS   Neumann,E., Engelsberg,A., Decker,J., Storkel,S., Jaeger,E.,
            Huber,C. and Seliger,B.
  TITLE     Heterogeneous expression of the tumor-associated antigens RAGE-1,
            PRAME, and glycoprotein 75 in human renal cell carcinoma:
            candidates for T-cell-based immunotherapies?
  JOURNAL   Cancer Res. 58 (18), 4090-4095 (1998)
   PUBMED   9751617
REFERENCE   7  (residues 1 to 509)
  AUTHORS   van Baren,N., Chambost,H., Ferrant,A., Michaux,L., Ikeda,H.,
            Millard,I., Olive,D., Boon,T. and Coulie,P.G.
  TITLE     PRAME, a gene encoding an antigen recognized on a human melanoma by
            cytolytic T cells, is expressed in acute leukaemia cells
  JOURNAL   Br. J. Haematol. 102 (5), 1376-1379 (1998)
   PUBMED   9753074
REFERENCE   8  (residues 1 to 509)
  AUTHORS   Williams,J.M., Chen,G.C., Zhu,L. and Rest,R.F.
  TITLE     Using the yeast two-hybrid system to identify human epithelial cell
            proteins that bind gonococcal Opa proteins: intracellular gonococci
            bind pyruvate kinase via their Opa proteins and require host
            pyruvate for growth
  JOURNAL   Mol. Microbiol. 27 (1), 171-186 (1998)
   PUBMED   9466265
REFERENCE   9  (residues 1 to 509)
  AUTHORS   Kirkin,A.F., Dzhandzhugazyan,K. and Zeuthen,J.
  TITLE     The immunogenic properties of melanoma-associated antigens
            recognized by cytotoxic T lymphocytes
  JOURNAL   Exp. Clin. Immunogenet. 15 (1), 19-32 (1998)
   PUBMED   9619397
  REMARK    Review article
REFERENCE   10 (residues 1 to 509)
  AUTHORS   Ikeda,H., Lethe,B., Lehmann,F., van Baren,N., Baurain,J.F., de
            Smet,C., Chambost,H., Vitale,M., Moretta,A., Boon,T. and
            Coulie,P.G.
  TITLE     Characterization of an antigen that is recognized on a melanoma
            showing partial HLA loss by CTL expressing an NK inhibitory
            receptor
  JOURNAL   Immunity 6 (2), 199-208 (1997)
   PUBMED   9047241
COMMENT     REVIEWED REFSEQ: This record has been curated by NCBI staff. The
            reference sequence was derived from BU151249.1, BC014074.2 and
            BC022008.1.
            
            Summary: This gene encodes an antigen that is predominantly
            expressed in human melanomas and that is recognized by cytolytic T
            lymphocytes. It is not expressed in normal tissues, except testis.
            This expression pattern is similar to that of other CT antigens,
            such as MAGE, BAGE and GAGE. However, unlike these other CT
            antigens, this gene is also expressed in acute leukemias. Five
            alternatively spliced transcript variants encoding the same protein
            have been observed for this gene. [provided by RefSeq].
            
            Transcript Variant: This variant (5) has multiple differences in
            the 5' UTR compared to the longest variant (2). Both variants
            encode the same protein.
            
            Publication Note:  This RefSeq record includes a subset of the
            publications that are available for this gene. Please see the
            Entrez Gene record to access additional publications.
FEATURES             Location/Qualifiers
     source          1..509
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="22"
                     /map="22q11.22"
     Protein         1..509
                     /product="preferentially expressed antigen in melanoma"
                     /note="melanoma antigen preferentially expressed in
                     tumors; Opa-interacting protein OIP4"
                     /calculated_mol_wt=57759
     CDS             1..509
                     /gene="PRAME"
                     /gene_synonym="MAPE"
                     /gene_synonym="OIP4"
                     /coded_by="NM_206956.1:287..1816"
                     /db_xref="CCDS:CCDS13801.1"
                     /db_xref="GeneID:23532"
                     /db_xref="HGNC:9336"
                     /db_xref="MIM:606021"
ORIGIN      
        1 merrrlwgsi qsryismsvw tsprrlvela gqsllkdeal aiaalellpr elfpplfmaa
       61 fdgrhsqtlk amvqawpftc lplgvlmkgq hlhletfkav ldgldvllaq evrprrwklq
      121 vldlrknshq dfwtvwsgnr aslysfpepe aaqpmtkkrk vdglsteaeq pfipvevlvd
      181 lflkegacde lfsyliekvk rkknvlrlcc kklkifampm qdikmilkmv qldsiedlev
      241 tctwklptla kfspylgqmi nlrrlllshi hassyispek eeqyiaqfts qflslqclqa
      301 lyvdslfflr grldqllrhv mnpletlsit ncrlsegdvm hlsqspsvsq lsvlslsgvm
      361 ltdvspeplq allerasatl qdlvfdecgi tddqllallp slshcsqltt lsfygnsisi
      421 salqsllqhl iglsnlthvl ypvplesyed ihgtlhlerl aylharlrel lcelgrpsmv
      481 wlsanpcphc gdrtfydpep ilcpcfmpn
//